- Home
- CPBI vs LUNG Comparison
CPBI vs LUNG Comparison
Compare CPBI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | LUNG |
|---|---|---|
| Founded | 2023 | 1995 |
| Country | United States | United States |
| Employees | N/A | 291 |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 72.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CPBI | LUNG |
|---|---|---|
| Price | $17.51 | $1.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.81 |
| AVG Volume (30 Days) | 3.3K | ★ 348.8K |
| Earning Date | 02-10-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.32 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | $19,961,000.00 | ★ $91,664,000.00 |
| Revenue This Year | N/A | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | $18.22 | ★ N/A |
| Revenue Growth | 9.30 | ★ 15.59 |
| 52 Week Low | $13.00 | $1.31 |
| 52 Week High | $17.70 | $9.37 |
Technical Indicators
Market Signals| Indicator | CPBI | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 60.40 | 37.89 |
| Support Level | $16.86 | $1.68 |
| Resistance Level | $17.70 | $1.92 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 77.38 | 15.40 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.